Historical tap News Stories
TAP: Q1 Strength, Q2 Shipment Warning Hits Stock
Molson Coors (TAP) posted solid Q1 results and unveiled a $450M cost‑savings plan, but flagged a 6–9% shipment drop in Q2 due to weather, energy and packaging disruptions—creating a mix of confidence and short‑term headwinds for the S&P 500 name.
Molson Coors Q1 Boosts EPS; Volume Worries Remain!
Molson Coors (TAP) reported Q1 results with robust margin gains and a $4B buyback push, but U.S. volume declines, supply snarls and lowered analyst sentiment keep near-term pressure on the stock.
Molson Coors (TAP) Insider Buys; Earnings April 30
Molson Coors (TAP) drew elevated media attention this week as insiders bought shares and the company set its Q1 2026 earnings release for April 30. Persistent share weakness, elevated short interest and a notable spike in coverage make the earnings report a clear near-term catalyst for the stock.
Molson Coors Acquires Monaco, $4B Buyback Set Now!
Molson Coors (TAP) moved decisively this week by acquiring Monaco Cocktails (Atomic Brands) to accelerate its RTD 'Beyond Beer' push, while expanding its share repurchase authorization to $4 billion. Coupled with a $450 million cost-savings program and ongoing volume pressures, these concrete actions aim to stabilize earnings and support TAP shares amid weak beer volumes and margin headwinds.
Molson Coors Drops; RTD Buy, Cost-Cut Risks Ahead!
Molson Coors (TAP) plunged to a 52-week low after cutting 2026 earnings guidance amid rising aluminum costs and soft volumes. The company is expanding into RTDs with the Monaco Cocktails deal and launching a $450M cost-savings program — but execution risk keeps upside limited near term.
Molson Coors' Atomic Brands Deal Boosts TAP Stock.
Molson Coors' March 2026 acquisition of Atomic Brands (Monaco Cocktails) marks a concrete step into the high-growth spirits-based RTD category. The deal could deliver modest top-line lift and accretion to earnings for TAP after recent impairments and volume headwinds in beer.
TAP Downgrade: Weak Volumes Hit Molson Coors Now!!
Analysts cut Molson Coors (TAP) to Underperform after weak quarterly results and a cautious conference presentation. Key issues: volume declines, a $3.9B goodwill impairment, and a 400-role restructuring as the company pivots beyond beer.
TAP Stock: Aluminum Costs Hit; Buybacks Boost Now!
Molson Coors (TAP) reported a mixed quarter: modest EPS beat but revenue miss, while a sharp rise in aluminum costs and continued volume weakness threaten margins. Management announced $450M in cost cuts, a $4B buyback plan and confirmed the dividend — moves that could stabilize cash flow but hinge on execution.
Molson Coors (TAP) Hit by Aluminum Costs, Cuts EPS
Molson Coors (TAP) saw analyst downgrades and weakened guidance this week after Q4 results showed falling volumes and rising packaging costs. Management lowered 2026 EPS guidance to $4.61–$4.82 and flagged an approximately $125M headwind from aluminum, prompting Bank of America to cut its rating and price target.
TAP: Molson Coors Adds Dividend, Expands Buybacks!
Molson Coors (TAP) posted mixed Q4 results: an EPS beat but revenue miss, announced a $0.48/share dividend, expanded buyback capacity, and launched a $450M cost-savings plan. Commodity inflation and soft demand drove guidance concerns, prompting analyst cuts and a near-term stock pullback despite stronger cash flow and lower leverage.
Molson Coors (TAP) Surges Amid Short-Term Momentum
Molson Coors (TAP) showed a brief run of outperformance Feb. 10–12, rising over 6% cumulatively before a pullback on Feb. 13. The gains reflected relative strength versus peers and the S&P 500, with no new corporate announcements driving the move—momentum and sector flows were the likely catalysts.
Molson Coors (TAP) Pullback Before Feb 18 Call Q4!
Molson Coors (TAP) saw a short-lived rally in early February before easing into a modest pullback as investors await Q4 results and a CAGNY presentation on Feb 18. No material corporate headlines emerged last week; price action reflected momentum, analyst caution (downgrades and lower price targets) and longer-term consumption questions tied to GLP-1 drugs. Key catalysts remain the Feb 18 earnings release and subsequent investor presentation.